Volume 20 Issue 12
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(12): 2010-2014
XIE Cai-xia, XUAN Ling, KANG Pin-fang, HUANG Yu-li, ZHANG Heng, TANG Bi. Influence of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure[J]. Chinese Journal of General Practice, 2022, 20(12): 2010-2014. doi: 10.16766/j.cnki.issn.1674-4152.002757
Citation: XIE Cai-xia, XUAN Ling, KANG Pin-fang, HUANG Yu-li, ZHANG Heng, TANG Bi. Influence of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure[J]. Chinese Journal of General Practice, 2022, 20(12): 2010-2014. doi: 10.16766/j.cnki.issn.1674-4152.002757
shu

Influence of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure

doi: 10.16766/j.cnki.issn.1674-4152.002757

  • Department of Cardiology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2018ZD023

 by51201214

  • Received Date: 2022-08-10
    Available Online: 2023-02-07
    Abstract
  •   Objective  By measuring the levels of blood cyclophilin A (CyPA), galectin-3, matrix metalloproteinase-2(MMP-2), MMP-9, N-terminal B type natriuretic peptide (NT-proBNP) in patients with chronic heart failure (CHF) before and after the application of sacubitril/valsartan, the effects of sacubitril/valsartan on related indexes of ventricular remodeling and cardiac function in patients with chronic heart failure were discussed.  Methods  We selected 99 cases with CHF treated with sacubitril/valsartan at the First Affiliated Hospital of Bengbu Medical College from December 2018 to June 2022. Blood samples were collected before and 3 months after treatment by sacubitril/valsartan, and the blood CyPA, galectin-3, MMP-2, MMP-9 and NT-proBNP levels before and after treatment by sacubitril/valsartan were compared.  Results  After treatment, the levels of blood CyPA, Galectin-3, MMP-2, MMP-9 and NT-proBNP in patients with CHF showed significant differences compared with those before treatment [CyPA: (7.75±3.18) ng/mL vs. (10.13±3.32) ng/mL; Galectin-3: (9.66±5.20) ng/mL vs. (16.74±3.18) ng/mL; MMP-2: (12.02±5.69) ng/mL vs. (18.40±8.41) ng/mL; MMP-9: (8.32±4.34) ng/mL vs. (11.45±4.51)ng/mL; NT-proBNP: (1 319.24±404.11) ng/mL vs. (4 187.48±1 967.92) ng/mL, all P < 0.01].  Conclusion  Sacubitril/valsartan can significantly reduce the levels of blood CyPA, Galectin-3, MMP-2, MMP-9 and NT-proBNP in patients with CHF and improve cardiac function, which may have certain effects on the evaluation of treatment with CHF.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    陈伟伟, 高润霖, 刘力生, 等. 《中国心血管病报告2017》概要[J]. 中国循环杂志, 2018, 33(1): 1-8. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201801001.htm
    [2]
    国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J]. 中国循环杂志, 2021, 36(3): 221-238. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202103002.htm
    [3]
    ZHANG Y H, ZHANG J, BUTLER J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: Results from the China heart failure (China-HF) registry[J]. J Card Fail, 2017, 23(12): 868-875. doi: 10.1016/j.cardfail.2017.09.014
    [4]
    中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [5]
    WANG L, WANG C H, JIA J F, et al. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis[J]. J Clin Immunol, 2010, 30(1): 24-33. doi: 10.1007/s10875-009-9329-1
    [6]
    YURCHENKO V, CONSTANT S, ELSENMESSER E, et al. Cyclophilin-CD147 interactions: A new target for anti-inflammatory therapeutics[J]. Clin Exp lmmunol, 2010, 160(3): 305-317. doi: 10.1111/j.1365-2249.2010.04115.x
    [7]
    BONFILS C, BEC N, LARROQUE C, et al. Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c[J]. Biochem Biophys Res Commun, 2010, 393(2): 325-330. doi: 10.1016/j.bbrc.2010.01.135
    [8]
    VAN DER VELDE A R, GULLESTAD L, UELAND T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: Data from CORONA and COACH[J]. Circ Heart Fail, 2013, 6(2): 219-226. doi: 10.1161/CIRCHEARTFAILURE.112.000129
    [9]
    滕海蛟. 慢性心衰患者CRT治疗前后血清NT-proBNP、MMP-9水平变化及意义[J]. 中国实用医药, 2017, 12(2): 125-127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201702061.htm
    [10]
    李彦芬, 陈春红, 王占起, 等. 沙库巴曲缬沙坦对心衰患者血浆NE、AngⅡ、ALD和血清sCD40L、sICAM-1、sFas、sFasL、以及cTnI、MMP-9水平的影响研究[J]. 海南医学院学报, 2018, 24(6): 665-668, 672. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYY201806003.htm
    [11]
    ROBERTS E, LUDMAN A J, DWORZYNSKI K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting[J]. BMJ, 2015, 350: h910. DOI: 10.1136/bmj.h910.
    [12]
    陈康玉, 严激. 安徽多中心前瞻性心力衰竭队列基线分析[J]. 中华全科医学, 2022, 20(1): 14-17, 98. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202201005.htm
    [13]
    BRAUNWALD E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure[J]. J Am Coll Cardiol, 2015, 65(10): 1029-1041.
    [14]
    MCMURRAY J J, PACKER M, DESAI A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004.
    [15]
    MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
    [16]
    宣玲, 唐碧, 康品方, 等. 血清亲环素A与慢性心力衰竭的关系[J]. 中国循环杂志, 2016, 31(3): 223-225. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201603007.htm
    [17]
    王剑锋, 凌华. 慢性心力衰竭患者血清可溶性细胞间黏附分子-1和半乳糖凝集素-3的表达及其临床意义[J]. 中华全科医学, 2020, 18(12): 2040-2042, 2143. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202012018.htm
    [18]
    MEUERS W C, VAN DER VELDE A R, DE BOER R A. The ARCHITECT galectin-3 assay: Comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure[J]. Expert Rev Mol Diagn, 2014, 14(3): 257-266.
    [19]
    YIN Q S, SHI B, DONG L, et al. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure[J]. J Geriatr Cardiol, 2014, 11(1): 79-82.
    [20]
    ZHANG Y H, ZHANG R C, AN T, et al. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure[J]. J Card Fail, 2015, 21(1): 51-59.
    [21]
    WANG H, CHEN Q Y, LI Y Y, et al. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: A prospective observational study[J]. Acta Cardiol, 2017, 72(2): 188-195.
    [22]
    王芳, 韦迎娜, 尹涛源. sST2、MMP-2、MMP-9与急性心肌梗死并发心力衰竭患者预后的相关性[J]. 安徽医学, 2020, 41(7): 755-759. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202007006.htm
    [23]
    王魏魏, 姜婷, 李华, 等. 评价BNPNT-proBNP对心力衰竭诊断价值的Meta分析[J]. 中国急救医学, 2015, 35(5): 418-425.
    [24]
    海澜, 雷晓亭, 王鹏. 血清Hcy及NT-pro-BNP与慢性心力衰竭患者临床预后的相关性研究[J]. 河北医学, 2020, 26(10): 1712-1715. https://www.cnki.com.cn/Article/CJFDTOTAL-HCYX202010030.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (270) PDF downloads(21) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return